Breaking News

Earlier this month, Locus entered into an exclusive collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. The agreement, facilitated by Johnson & Johnson Innovation, includes an initial investment of $20 million and is potentially worth up to $818 million. The partnership is focused on the development and manufacturing of CRISPR-Cas3-enhanced bacteriophage products targeting two key bacterial pathogens of the respiratory tract and other organ systems. After the deal, Locus will retain all rights to the technology and its application to other pathogens.

LEARN MORE

Research Commercialization News

NC State Spinout Locus Biosciences Inks Historic Licensing Deal

NC State provides innovators with a range of programs and services to develop, protect, market and commercialize inventions developed at the university through the licensing of intellectual property or the launch of new companies based...

Continue reading "NC State Spinout Locus Biosciences Inks Historic Licensing Deal"

Howling Cow Ice Cream Available in Harris Teeter Stores

A State Fair and NC State campus delectable treat is now available for the first time in grocery retail locations across parts of the Triangle. Six different flavors of Howling Cow® ice cream can be purchased...

Continue reading "Howling Cow Ice Cream Available in Harris Teeter Stores"

Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics

Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage ("crPhage™") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems.  Johnson & Johnson Innovation LLC facilitated the transaction.

View More Research Commercialization News

NSF ICorps Logo

NC State’s I-Corps Program

Are you interested in learning more about how your research would fit into the marketplace? NC State’s I-Corps Site provides training and funding to help you better understand how your solution fits in the marketplace and improve the prospects of attracting funding.


We are proud sponsors of the 2019 #CEDTechCon Feb 25-26. Register now for the premier #Triangle #Tech event… https://t.co/jnwJa3NO8a
h J R
The third day of #AUTM2019 is underway! Starting with Counting Success: Why #Metrics don’t work anymore. “If we are… https://t.co/LhJF5vVN9C
h J R
On the second day of #AUTM2019! Great panel on Industry Perspective for Proven Marketing Techniques to License Tech… https://t.co/jEMMZAxh8B
h J R
RT @AUTM: @labunleashed takes the stage for the morning keynote at #AUTM2019! "I realized that ideas are everywhere. I think of ideas like…
h J R

1010+
Patents Issued

141+
New License and Option Agreements

135+
Startups Launched

3,600+
Jobs Created in North Carolina

$1.7B+
in Financing Raised by
NC State Startups

595+
Products to Market

Research Commercialization Events

View Detailed List with Links | View on Google Calendar